Vesalius Biocapital I

Inflammatix is a molecular diagnostics company based in Burlingame, California, founded in 2016. It specializes in developing rapid tests that analyze the immune system to address significant clinical and public health issues. The company's initial focus is on creating tests for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix also builds a diagnostics pipeline based on host response, which includes tests for tropical infections, autoimmune diseases, transplant rejection, and other conditions.

Caresyntax Inc. is a Boston-based company that provides a digital surgery platform to enhance surgical performance in hospitals and ambulatory surgical centers. Founded in 1991, it leverages data from over 1,600 hospitals globally to deliver insights that improve patient outcomes and operational efficiency. The platform integrates various data sources, including video, audio, clinical, and operational data, enabling real-time analysis and decision-making during surgeries. Caresyntax offers solutions such as qvident, a performance management software, and PRIME365, a comprehensive integration platform that consolidates surgical data and content. With a focus on automating workflows and reducing surgical variability, Caresyntax supports over 4,000 operating rooms and has facilitated millions of surgical procedures worldwide. The company’s HIPAA-compliant software can be deployed on-premise, in the cloud, or in a hybrid format, making it adaptable to diverse healthcare environments.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.

inHEART is a company focused on advancing cardiac care through innovative software solutions that utilize artificial intelligence. It specializes in creating a digital twin of the heart, which allows for enhanced medical image analysis and cardiac modeling, particularly for heart rhythm disorders. By bridging the gap between radiology and cardiology, inHEART aims to develop an image-guided diagnosis and therapy planning platform that facilitates personalized treatment and prevention strategies for conditions such as cardiac arrhythmias, heart failure, and stroke. This technology transforms preoperative medical images into a detailed representation of the patient's heart, empowering cardiologists to plan procedures more effectively and navigate instruments with greater precision, ultimately leading to reduced procedure duration and lower failure rates.

Cognivia is a company that focuses on developing analytical tools aimed at optimizing and accelerating the clinical development of new medicines. Its innovative tools employ predictive techniques to enhance the clinical evaluation of drugs and other therapeutics. By addressing and mitigating the variability in clinical trial data, Cognivia enables its clients to identify and manage critical sources of variability, ultimately improving the efficiency and effectiveness of clinical trials.

Tonic App S.A. is a mobile application developer based in Porto, Portugal, founded in 2016. The company’s flagship application serves as a comprehensive platform for medical professionals, facilitating communication, collaboration, and information sharing among doctors. It enables users to message, share, and archive patient cases, seek expert advice, and network with peers. Tonic App is also utilized by hospitals, pharmaceutical and medical technology firms, as well as medical associations, to connect with healthcare professionals and disseminate relevant medical content. The application supports various functionalities including video consultations, clinical decision tools, and the sharing of medical images, thereby enhancing clinical work efficiency and improving patient outcomes. It is accredited as an e-library by the European Accreditation Council in CME, underscoring its commitment to quality and safety in clinical practices.

Memo Therapeutics AG is a Swiss biotechnology company based in Basel, specializing in antibody discovery and immune repertoire analysis. The company has developed the MemoMAB platform, which generates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, creating a comprehensive library of unique antibodies. This innovative technology allows for the identification of a vast array of relevant and rare antibodies, significantly enhancing the potential for immune repertoire analysis and antibody discovery. Memo Therapeutics aims to leverage its platform in proprietary antibody lead discovery programs and through collaborations, with a focus on improving treatment options for patients suffering from viral infections and cancer.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

Scenic Biotech, established in 2017 and headquartered in Amsterdam, Netherlands, specializes in developing genomics and immunotherapy technologies to combat cancer and rare genetic diseases. The company's core focus is to identify and harness disease-suppressing genes, which can act as an "off-switch" for genetic disorders, thereby creating novel drug targets and therapies. By leveraging genomics, Scenic Biotech aims to revolutionize the treatment of severe diseases by tackling them at the genetic level.

Memo Therapeutics AG is a Swiss biotechnology company based in Basel, specializing in antibody discovery and immune repertoire analysis. The company has developed the MemoMAB platform, which generates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, creating a comprehensive library of unique antibodies. This innovative technology allows for the identification of a vast array of relevant and rare antibodies, significantly enhancing the potential for immune repertoire analysis and antibody discovery. Memo Therapeutics aims to leverage its platform in proprietary antibody lead discovery programs and through collaborations, with a focus on improving treatment options for patients suffering from viral infections and cancer.

Rejuvenate Biomed is a biomedical company focused on researching the biology of aging to develop safe and effective drugs aimed at maintaining and restoring cellular resilience. The company utilizes large datasets and network biology to identify synergistic drug combinations that can delay the onset of age-related diseases. By understanding and addressing the complex biological systems associated with aging, Rejuvenate Biomed seeks to improve responses to age-related conditions and enhance overall health.

Caresyntax Inc. is a Boston-based company that provides a digital surgery platform to enhance surgical performance in hospitals and ambulatory surgical centers. Founded in 1991, it leverages data from over 1,600 hospitals globally to deliver insights that improve patient outcomes and operational efficiency. The platform integrates various data sources, including video, audio, clinical, and operational data, enabling real-time analysis and decision-making during surgeries. Caresyntax offers solutions such as qvident, a performance management software, and PRIME365, a comprehensive integration platform that consolidates surgical data and content. With a focus on automating workflows and reducing surgical variability, Caresyntax supports over 4,000 operating rooms and has facilitated millions of surgical procedures worldwide. The company’s HIPAA-compliant software can be deployed on-premise, in the cloud, or in a hybrid format, making it adaptable to diverse healthcare environments.

Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.

Rejuvenate Biomed is a biomedical company focused on researching the biology of aging to develop safe and effective drugs aimed at maintaining and restoring cellular resilience. The company utilizes large datasets and network biology to identify synergistic drug combinations that can delay the onset of age-related diseases. By understanding and addressing the complex biological systems associated with aging, Rejuvenate Biomed seeks to improve responses to age-related conditions and enhance overall health.

Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.

Catalym GmbH, established in Munich, Germany in 2016, is a biotechnology company dedicated to developing innovative immunotherapies for cancer patients. The company focuses on neutralizing GDF-15, a central regulator of the immune system in the tumor microenvironment, aiming to demonstrate clinical proof-of-concept across multiple solid tumor indications with its lead program CTL-002. Catalym's mission is to transform cancer patients' lives by engaging their own immune systems and improving treatment options.

Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.

Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.

OncoDNA is a theranostic and genomic company that specializes in precision medicine for cancer and genetic diseases. Founded by a team with over 60 years of experience in medical diagnostics, the company focuses on providing clinical guidance for the treatment and real-time monitoring of late-stage cancer patients. OncoDNA supports researchers and biopharma companies in navigating the complexities of molecular biology, facilitating research and drug development in oncology. With its commitment to delivering precision medicine, OncoDNA aims to enhance treatment outcomes and improve the management of cancer and genetic disorders.

Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of customized orthopedic aids. The company's product range includes orthoses, prostheses, and related equipment, with notable offerings such as Mecuris FirStep, Mecuris NexStep, Mecuris cover, and the Mecuris Solution Platform. Mecuris aims to revolutionize the orthotics and prosthetics (O&P) industry by leveraging digital technology and 3D printing. Their platform uses patient data and scans to semi-automatically create individualized 3D designs for patient aids, which can be printed locally. This approach significantly reduces production times, enabling a fully customized fit, functionality, and appearance for wearers. Mecuris collaborates with O&P professionals to co-create these custom products, enhancing the lives of patients through innovative digital solutions.

Tonic App S.A. is a mobile application developer based in Porto, Portugal, founded in 2016. The company’s flagship application serves as a comprehensive platform for medical professionals, facilitating communication, collaboration, and information sharing among doctors. It enables users to message, share, and archive patient cases, seek expert advice, and network with peers. Tonic App is also utilized by hospitals, pharmaceutical and medical technology firms, as well as medical associations, to connect with healthcare professionals and disseminate relevant medical content. The application supports various functionalities including video consultations, clinical decision tools, and the sharing of medical images, thereby enhancing clinical work efficiency and improving patient outcomes. It is accredited as an e-library by the European Accreditation Council in CME, underscoring its commitment to quality and safety in clinical practices.

Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, established in 2013. The company specializes in creating novel therapeutic drugs that address urological and endocrinological diseases by focusing on tissue-specific regulation of sex hormone effects. Among its key developments is Fispemifene, a selective estrogen receptor modulator aimed at treating low testosterone symptoms in men. Forendo Pharma also works on a 17HSD1-inhibitor targeting endometriosis, thereby addressing broader gynecological conditions. Through its innovative approach, the company seeks to enhance treatment options for both men's and women's health, particularly in areas that have previously been underserved.

DEARHealth is a health technology company based in Beverly Hills, California, founded in 2013. It specializes in developing a Software as a Service (SaaS) based healthcare management platform tailored for medical providers and health insurers. The company leverages advanced data analytics to create disease-specific, coordinated care pathways that enhance provider workflows, support organizational decision-making, and engage patients through dedicated apps. DEARHealth's solutions are designed to improve health outcomes and experiences for chronically ill patients while reducing costs, with a focus on value-based healthcare.

Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of customized orthopedic aids. The company's product range includes orthoses, prostheses, and related equipment, with notable offerings such as Mecuris FirStep, Mecuris NexStep, Mecuris cover, and the Mecuris Solution Platform. Mecuris aims to revolutionize the orthotics and prosthetics (O&P) industry by leveraging digital technology and 3D printing. Their platform uses patient data and scans to semi-automatically create individualized 3D designs for patient aids, which can be printed locally. This approach significantly reduces production times, enabling a fully customized fit, functionality, and appearance for wearers. Mecuris collaborates with O&P professionals to co-create these custom products, enhancing the lives of patients through innovative digital solutions.

OMEICOS Therapeutics GmbH is a biotechnology company based in Berlin, Germany, founded in 2013. The company focuses on developing innovative small molecule therapeutics aimed at preventing and treating cardiovascular diseases, as well as addressing inflammatory and ophthalmic conditions. OMEICOS has pioneered a novel therapeutic approach that leverages natural metabolites of omega-3 fatty acids, which exhibit a strong anti-arrhythmic effect. Its unique substances activate an endogenous cardio-protective signaling pathway, distinguishing them from traditional anti-arrhythmic drugs by not only stabilizing heart rhythm but also potentially providing curative effects by preventing electrical and structural remodeling of the heart. This technology allows for the development of metabolically robust synthetic analogs of Epoxyeicosanoids, enabling safer treatment options for cardiovascular ailments.

Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, established in 2013. The company specializes in creating novel therapeutic drugs that address urological and endocrinological diseases by focusing on tissue-specific regulation of sex hormone effects. Among its key developments is Fispemifene, a selective estrogen receptor modulator aimed at treating low testosterone symptoms in men. Forendo Pharma also works on a 17HSD1-inhibitor targeting endometriosis, thereby addressing broader gynecological conditions. Through its innovative approach, the company seeks to enhance treatment options for both men's and women's health, particularly in areas that have previously been underserved.

Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.

Ncardia is a biotechnology company focused on expediting the drug discovery and development process. Utilizing human induced pluripotent stem cell (hiPSC) technology, Ncardia develops predictive human cellular assay systems that facilitate safety and efficacy testing of drug candidates. The company's innovations enhance cardiovascular and neural drug screening, allowing researchers and drug discovery firms to incorporate predictive human disease biology into their processes. Through its advanced technologies, Ncardia aims to accelerate the overall drug discovery timeline, ultimately improving the efficiency and effectiveness of bringing new therapeutics to market.

OMEICOS Therapeutics GmbH is a biotechnology company based in Berlin, Germany, founded in 2013. The company focuses on developing innovative small molecule therapeutics aimed at preventing and treating cardiovascular diseases, as well as addressing inflammatory and ophthalmic conditions. OMEICOS has pioneered a novel therapeutic approach that leverages natural metabolites of omega-3 fatty acids, which exhibit a strong anti-arrhythmic effect. Its unique substances activate an endogenous cardio-protective signaling pathway, distinguishing them from traditional anti-arrhythmic drugs by not only stabilizing heart rhythm but also potentially providing curative effects by preventing electrical and structural remodeling of the heart. This technology allows for the development of metabolically robust synthetic analogs of Epoxyeicosanoids, enabling safer treatment options for cardiovascular ailments.

Exact Imaging is a Canadian company based in Markham that specializes in developing high-resolution micro-ultrasound systems for urological applications, particularly in the diagnosis and treatment of prostate cancer. The flagship ExactVu system operates at 29 MHz, providing exceptional imaging resolution that allows for the visualization and targeting of suspicious regions within the prostate. This technology facilitates both targeted and systematic TRUS biopsies, enhancing the accuracy of prostate cancer diagnostics. Additionally, Exact Imaging offers the FusionVu application, which integrates micro-ultrasound with MRI data to further improve imaging and biopsy guidance. Founded in 2003 and originally named Imagistx, Inc., the company rebranded to Exact Imaging in March 2015.

Promethera Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver diseases. Founded in 2009 and based in Mont-Saint-Guibert, Belgium, with an office in Tokyo, Japan, the company specializes in cell therapy products, notably HepaStem and H2Stem, which utilize allogeneic progenitor cells derived from healthy human adult livers. Promethera is actively working on treatments for a range of conditions, including acute-on-chronic liver failure, hemophilia, liver fibrosis, non-alcoholic steatohepatitis, liver-based metabolic diseases, and urea cycle disorders. The company also engages in strategic alliances to further its research and development efforts, enhancing its capacity to discover and commercialize effective cell therapies for liver-related ailments.

Ogeda SA is a clinical-stage drug discovery company based in Gosselies, Belgium, that specializes in the invention and development of small molecule drugs targeting G-Protein Coupled Receptors (GPCRs). Founded in 1994 and formerly known as Euroscreen, the company focuses on developing innovative therapies for women's health disorders, with its lead product, fezolinetant, currently in Phase II clinical development. In addition to fezolinetant, Ogeda is advancing other small molecules aimed at treating various endocrine, central nervous system, and inflammatory conditions. The company maintains facilities in Brussels and Paris, and operates as a subsidiary of Astellas Pharma Inc. Through its research, Ogeda seeks to provide effective treatment options for hormone-dependent pathologies and other related health issues.

Apitope is a biotechnology company dedicated to discovering and developing disease-modifying therapies for autoimmune and allergic diseases. Its research primarily targets conditions such as multiple sclerosis, Graves’ disease, Factor VIII intolerance, and uveitis. Utilizing a proprietary platform technology, Apitope develops antigen-specific therapeutic peptides aimed at addressing the underlying causes of these diseases. The company’s innovative approach seeks to enhance patients' quality of life by providing treatments that minimize the risk of secondary infections and complications. Apitope's first product candidate has been licensed to a major pharmaceutical partner, Merck Serono, while the company continues to advance its remaining portfolio of therapeutic candidates.

OMEICOS Therapeutics GmbH is a biotechnology company based in Berlin, Germany, founded in 2013. The company focuses on developing innovative small molecule therapeutics aimed at preventing and treating cardiovascular diseases, as well as addressing inflammatory and ophthalmic conditions. OMEICOS has pioneered a novel therapeutic approach that leverages natural metabolites of omega-3 fatty acids, which exhibit a strong anti-arrhythmic effect. Its unique substances activate an endogenous cardio-protective signaling pathway, distinguishing them from traditional anti-arrhythmic drugs by not only stabilizing heart rhythm but also potentially providing curative effects by preventing electrical and structural remodeling of the heart. This technology allows for the development of metabolically robust synthetic analogs of Epoxyeicosanoids, enabling safer treatment options for cardiovascular ailments.

Genkyotex SA is a biopharmaceutical company focused on developing innovative oral small molecule therapies that selectively inhibit NOX enzymes involved in various disease processes, including fibrosis, inflammation, pain, cancer, and neurodegeneration. Its lead candidate, GKT831, targets NOX1 and NOX4 and is currently undergoing Phase II clinical trials for primary biliary cholangitis and type 1 diabetes-related kidney disease. Additionally, Genkyotex is advancing a preclinical candidate, GKT771, which inhibits NOX1 and aims to address pain processing and inflammation. The company also holds a license agreement with the Serum Institute of India for GTL003, an antigen intended for developing combination vaccines against infectious diseases. Established in 2006 and headquartered in Labège, France, Genkyotex is committed to improving treatment options for chronic diseases through its novel therapeutic approaches.

Humedics GmbH, founded in 2009 and based in Berlin, Germany, specializes in developing innovative solutions for liver function assessment. The company's flagship product, the LiMAx test, is a breath analysis device that enables real-time measurement of liver function in patients with liver failure. This easy-to-use bedside system includes a medical device, breath masks, and a diagnostic drug, allowing clinicians to accurately quantify liver function capacity. The LiMAx test is utilized in various clinical applications, such as evaluating liver function prior to and following liver transplantation, planning for living donor liver resection, and assessing conditions like liver cirrhosis. With its technology already benefiting thousands of patients, Humedics is actively expanding its global operations to enhance patient outcomes through tailored medical treatment.

Ncardia is a biotechnology company focused on expediting the drug discovery and development process. Utilizing human induced pluripotent stem cell (hiPSC) technology, Ncardia develops predictive human cellular assay systems that facilitate safety and efficacy testing of drug candidates. The company's innovations enhance cardiovascular and neural drug screening, allowing researchers and drug discovery firms to incorporate predictive human disease biology into their processes. Through its advanced technologies, Ncardia aims to accelerate the overall drug discovery timeline, ultimately improving the efficiency and effectiveness of bringing new therapeutics to market.

Trod Medical S.A. is a medical device manufacturer founded in 2006, with its headquarters located in Leuven, Belgium, and a presence in the Tampa Bay area, USA. The company specializes in innovative ablation technologies, particularly in the development of radiofrequency (RF) ablation devices. Trod Medical's flagship product, the EncageTM, is a percutaneous RF device designed to ablate soft tissues with exceptional precision, significantly reducing collateral damage compared to conventional treatments. This advancement is particularly relevant in the treatment of prostate cancer, a prevalent condition that affects around 240,000 new patients annually in the United States. The company aims to address the limitations of existing therapies, which often lead to serious side effects such as erectile dysfunction and urinary incontinence. Through its focus on focal ablation techniques, Trod Medical is committed to improving patient outcomes and enhancing surgical efficacy.

Complix is a biopharmaceutical company dedicated to the discovery and development of Alphabodies™, a novel class of therapeutics that provide distinct advantages over traditional protein-based treatments. These Alphabodies™ exhibit high affinity binding to a diverse array of disease targets, particularly those that are challenging for conventional antibodies to access. The company focuses on developing its pipeline of Alphabody therapeutics to address intracellular disease targets integral to conditions such as cancer, autoimmunity, and viral diseases. By merging the targeted potency of biologics with the stability and cell-penetrating capabilities of small molecules, Complix aims to overcome the limitations associated with conventional antibodies and small molecule drugs, thereby providing innovative solutions for patients facing intractable health issues.

FF Pharma is a biopharmaceutical company focused on developing innovative therapies for chronic inflammatory diseases, specifically targeting conditions such as primary biliary cirrhosis and Crohn’s disease. The company is advancing an anti-CD40 monoclonal antibody therapy that acts as a negative allosteric modulator of the CD40 pathway. This therapy serves as a reversible switch for B cell activation, inhibiting aberrant immune responses associated with autoimmune diseases. By targeting the CD40 pathway, FF Pharma aims to provide effective treatment options for patients suffering from chronic inflammation and related disorders.

Ogeda SA is a clinical-stage drug discovery company based in Gosselies, Belgium, that specializes in the invention and development of small molecule drugs targeting G-Protein Coupled Receptors (GPCRs). Founded in 1994 and formerly known as Euroscreen, the company focuses on developing innovative therapies for women's health disorders, with its lead product, fezolinetant, currently in Phase II clinical development. In addition to fezolinetant, Ogeda is advancing other small molecules aimed at treating various endocrine, central nervous system, and inflammatory conditions. The company maintains facilities in Brussels and Paris, and operates as a subsidiary of Astellas Pharma Inc. Through its research, Ogeda seeks to provide effective treatment options for hormone-dependent pathologies and other related health issues.

Genkyotex SA is a biopharmaceutical company focused on developing innovative oral small molecule therapies that selectively inhibit NOX enzymes involved in various disease processes, including fibrosis, inflammation, pain, cancer, and neurodegeneration. Its lead candidate, GKT831, targets NOX1 and NOX4 and is currently undergoing Phase II clinical trials for primary biliary cholangitis and type 1 diabetes-related kidney disease. Additionally, Genkyotex is advancing a preclinical candidate, GKT771, which inhibits NOX1 and aims to address pain processing and inflammation. The company also holds a license agreement with the Serum Institute of India for GTL003, an antigen intended for developing combination vaccines against infectious diseases. Established in 2006 and headquartered in Labège, France, Genkyotex is committed to improving treatment options for chronic diseases through its novel therapeutic approaches.

Trinean is a Belgium-based technology provider specializing in micro-volume molecular spectroscopy. Founded in 2006 as a spin-out from Ghent University and Imec Leuven, the company develops UV/VIS spectrometers for biomolecule quantification. Their flagship products, the DropSense™16 and DropSense™96, analyze up to 16 and 96 samples respectively, utilizing microfluidic chips for standardized sample analysis through DropPlates™ and Slides. Trinean's platform is enhanced with a software toolbox designed to improve data interpretation and lab automation, catering to the needs of biologics researchers.

Amakem is a kinase platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. Amakem's product pipeline is based on its unique ‘Localized Drug Action' platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.

ProFibrix B.V. is a biotechnology company focused on developing and marketing innovative products for the hemostasis and regenerative medicine sectors. Founded in 2004, the company specializes in Fibrocaps, a dry powder topical hemostat and tissue sealant designed to effectively control acute and severe bleeding during surgical procedures or due to traumatic injuries. Fibrocaps is formulated from a blend of fibrinogen and thrombin, two key proteins vital for blood clotting and tissue repair. Additionally, ProFibrix offers a sterilized single-use delivery device that facilitates the application of Fibrocaps to targeted areas, minimizing the need to manipulate the wound in a surgical setting. The company's products leverage human fibrinogen, a natural blood protein, to enhance hemostatic efficacy and promote healing.

Genkyotex SA is a biopharmaceutical company focused on developing innovative oral small molecule therapies that selectively inhibit NOX enzymes involved in various disease processes, including fibrosis, inflammation, pain, cancer, and neurodegeneration. Its lead candidate, GKT831, targets NOX1 and NOX4 and is currently undergoing Phase II clinical trials for primary biliary cholangitis and type 1 diabetes-related kidney disease. Additionally, Genkyotex is advancing a preclinical candidate, GKT771, which inhibits NOX1 and aims to address pain processing and inflammation. The company also holds a license agreement with the Serum Institute of India for GTL003, an antigen intended for developing combination vaccines against infectious diseases. Established in 2006 and headquartered in Labège, France, Genkyotex is committed to improving treatment options for chronic diseases through its novel therapeutic approaches.

Activaero GmbH is a drug delivery company specializing in controlled breathing technologies designed for the pulmonary delivery of inhaled therapeutic agents. Founded in 2004 and based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero develops innovative devices such as AKITA, which utilizes smart card technology for efficient drug delivery, and Watchhaler, specifically designed for children requiring inhaled medication. The company also offers AKITA², a technology for use in clinical trials, and LimiX, a flow limitation valve that regulates inhalation flow rates. In addition to its product offerings, Activaero provides measurement and diagnostic technologies for laboratory applications, including aerosol property measurement systems. Furthermore, the company engages in contract development and clinical trial logistics services, marketing its products through a network of distributors. Activaero's solutions aim to improve therapy outcomes for patients suffering from severe respiratory diseases, including asthma, chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis.

Complix is a biopharmaceutical company dedicated to the discovery and development of Alphabodies™, a novel class of therapeutics that provide distinct advantages over traditional protein-based treatments. These Alphabodies™ exhibit high affinity binding to a diverse array of disease targets, particularly those that are challenging for conventional antibodies to access. The company focuses on developing its pipeline of Alphabody therapeutics to address intracellular disease targets integral to conditions such as cancer, autoimmunity, and viral diseases. By merging the targeted potency of biologics with the stability and cell-penetrating capabilities of small molecules, Complix aims to overcome the limitations associated with conventional antibodies and small molecule drugs, thereby providing innovative solutions for patients facing intractable health issues.

Promethera Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver diseases. Founded in 2009 and based in Mont-Saint-Guibert, Belgium, with an office in Tokyo, Japan, the company specializes in cell therapy products, notably HepaStem and H2Stem, which utilize allogeneic progenitor cells derived from healthy human adult livers. Promethera is actively working on treatments for a range of conditions, including acute-on-chronic liver failure, hemophilia, liver fibrosis, non-alcoholic steatohepatitis, liver-based metabolic diseases, and urea cycle disorders. The company also engages in strategic alliances to further its research and development efforts, enhancing its capacity to discover and commercialize effective cell therapies for liver-related ailments.

Activaero GmbH is a drug delivery company specializing in controlled breathing technologies designed for the pulmonary delivery of inhaled therapeutic agents. Founded in 2004 and based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero develops innovative devices such as AKITA, which utilizes smart card technology for efficient drug delivery, and Watchhaler, specifically designed for children requiring inhaled medication. The company also offers AKITA², a technology for use in clinical trials, and LimiX, a flow limitation valve that regulates inhalation flow rates. In addition to its product offerings, Activaero provides measurement and diagnostic technologies for laboratory applications, including aerosol property measurement systems. Furthermore, the company engages in contract development and clinical trial logistics services, marketing its products through a network of distributors. Activaero's solutions aim to improve therapy outcomes for patients suffering from severe respiratory diseases, including asthma, chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis.

Apitope is a biotechnology company dedicated to discovering and developing disease-modifying therapies for autoimmune and allergic diseases. Its research primarily targets conditions such as multiple sclerosis, Graves’ disease, Factor VIII intolerance, and uveitis. Utilizing a proprietary platform technology, Apitope develops antigen-specific therapeutic peptides aimed at addressing the underlying causes of these diseases. The company’s innovative approach seeks to enhance patients' quality of life by providing treatments that minimize the risk of secondary infections and complications. Apitope's first product candidate has been licensed to a major pharmaceutical partner, Merck Serono, while the company continues to advance its remaining portfolio of therapeutic candidates.

Trinean is a Belgium-based technology provider specializing in micro-volume molecular spectroscopy. Founded in 2006 as a spin-out from Ghent University and Imec Leuven, the company develops UV/VIS spectrometers for biomolecule quantification. Their flagship products, the DropSense™16 and DropSense™96, analyze up to 16 and 96 samples respectively, utilizing microfluidic chips for standardized sample analysis through DropPlates™ and Slides. Trinean's platform is enhanced with a software toolbox designed to improve data interpretation and lab automation, catering to the needs of biologics researchers.

Genomic Vision is a biotechnology company specializing in molecular diagnostics and technology. It utilizes its proprietary Molecular Combing technology, which allows for the detection of single DNA molecules, to develop and commercialize innovative genetic tests and research tools. The company's products are primarily focused on DNA analysis and genetic testing, addressing areas such as cancer, rare inherited disorders, and pharmacogenomics. Through its advancements in biomarker discovery and DNA detection, Genomic Vision aims to enhance research capabilities and improve clinical outcomes in the life sciences sector.